Semarion
Develops next-generation cell assay technology for drug discovery
$3.8MUndisclosed
Role not disclosedCE
Cambridge Enterprise Ventures
Activity from announced rounds
Activity in this selectionMar 31, 2026 · Mar 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $19.4M 2 disclosed · full round size, not this investor’s share